Inhibikase Therapeutics, Inc. IKT

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
54/100
Moderate

Ranked against 712 peers in Biotechnology

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate … Full IKT analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.86), suggesting sticky customer base.
  • Strong Liquidity Buffer Liquidity position is strong (score 0.94), providing operational cushion.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.24), raising refinancing risk.
  • Weak or Negative Cash Flow Cash generation is weak (score 0.00), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where IKT ranks in Biotechnology

Inhibikase Therapeutics, Inc. ranks #184 of 713 scored companies in Biotechnology by moat score — the top 26%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
180 Celularity Inc. CELU 55/100 Moderate
181 Celularity Inc. CELUW 55/100 Moderate
182 Fennec Pharmaceuticals Inc. FENC 55/100 Moderate
183 Axsome Therapeutics, Inc. AXSM 54/100 Moderate
184 Inhibikase Therapeutics, Inc. IKT 54/100 Moderate
185 REGENXBIO Inc. RGNX 54/100 Moderate
186 Cue Biopharma, Inc. CUE 54/100 Moderate
187 Lineage Cell Therapeutics, Inc. LCTX 54/100 Moderate
188 Fulcrum Therapeutics, Inc. FULC 54/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How IKT scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 86 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 44 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 50 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding IKT's moat

What is Inhibikase Therapeutics, Inc.'s moat score?

Inhibikase Therapeutics, Inc. (IKT) scores 54 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #184 of 713 scored companies in Biotechnology, the top 26%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (86/100) and its weakest is Capital Efficiency (44/100).

How does Inhibikase Therapeutics, Inc. compare with other Biotechnology companies?

Inhibikase Therapeutics, Inc. ranks #184 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Axsome Therapeutics, Inc. (AXSM) at 54 just above it and REGENXBIO Inc. (RGNX) at 54 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Inhibikase Therapeutics, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Inhibikase Therapeutics, Inc.?

The Corporate Default template measures 6 defenses, and IKT scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (86), Capital Efficiency (44), Resilience (50), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000